Orca Bio has treated approximately 400 patients in clinical trials
Ivan Dimov · Ep 83: A New Leukemia Cure with Ivan Dimov of Orca Bio · Joe Lonsdale · Apr 5, 2024 · at 9:01
Ivan Dimov is the CEO of Orca Bio, discussing the clinical progress and scale of the company's precision cell therapy trials.
0:00 / 0:05exact quote · 5.6s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“We treated about 400 or so folks with a couple of different products that we have in the clinic right now.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Ivan Dimov
Orca Bio clinical data shows practically zero transplant-related patient mortalities
“Well, we'll see, but the data so far suggests that we can bring it down to practically zero, right? Zero transplant related mortalities.”
Novartis shut down Irv Weissman's promising breast cancer cell therapy program
“They had really incredible results in terminal breast cancer patients, and it was ultimately acquired by Sandoz slash Novartis, and everyone thought that was going to be delivered to patients, but You know, they shut down the whole program two years later, and…”
Immune resets for leukemia patients have serendipitously eliminated MS and HIV
“There are sort of serendipitous situations where people have had, for example, really severe autoimmune diseases like multiple sclerosis, happen to also have leukemia on the side. For the leukemia, they get an immune system reset, and then they, you know, magi…”
Safe immune resets could eventually treat tens of millions of patients
“And I think the, you know, ultimately, if this keeps progressing the way that we've seen it so far, there's no reason why you couldn't be helping tens of millions of patients.”
Orca Bio must compress multi-year drug distribution cycles into 72 hours
“If you look at a regular medicine from the moment you get the raw material until you ship it to the factory, you build the pills and then you ship, you have the whole distribution network and all the warehousing until it gets to the hospital and ultimately get…”
Single-dose curative cell therapies disrupt healthcare payment models requiring upfront billing
“Because you have to condense all of the regular payments that you do when you take a pill. You might take a pill for many years. You have to condense them all into one payment because at the end of the day, this is a single dose curative medicine.”